188 related articles for article (PubMed ID: 20720042)
1. Whole-body biodistribution and radiation dosimetry of 18F-FP-(+)-DTBZ (18F-AV-133): a novel vesicular monoamine transporter 2 imaging agent.
Lin KJ; Weng YH; Wey SP; Hsiao IT; Lu CS; Skovronsky D; Chang HP; Kung MP; Yen TC
J Nucl Med; 2010 Sep; 51(9):1480-5. PubMed ID: 20720042
[TBL] [Abstract][Full Text] [Related]
2. Deuterated
Liu F; Choi SR; Zha Z; Ploessl K; Zhu L; Kung HF
Nucl Med Biol; 2018 Feb; 57():42-49. PubMed ID: 29306111
[TBL] [Abstract][Full Text] [Related]
3. In vivo imaging of beta-cell mass in rats using 18F-FP-(+)-DTBZ: a potential PET ligand for studying diabetes mellitus.
Kung MP; Hou C; Lieberman BP; Oya S; Ponde DE; Blankemeyer E; Skovronsky D; Kilbourn MR; Kung HF
J Nucl Med; 2008 Jul; 49(7):1171-6. PubMed ID: 18552132
[TBL] [Abstract][Full Text] [Related]
4. Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent--a pilot study.
Lin KJ; Hsu WC; Hsiao IT; Wey SP; Jin LW; Skovronsky D; Wai YY; Chang HP; Lo CW; Yao CH; Yen TC; Kung MP
Nucl Med Biol; 2010 May; 37(4):497-508. PubMed ID: 20447562
[TBL] [Abstract][Full Text] [Related]
5. In vivo imaging of vesicular monoamine transporter 2 in pancreas using an (18)F epoxide derivative of tetrabenazine.
Kung HF; Lieberman BP; Zhuang ZP; Oya S; Kung MP; Choi SR; Poessl K; Blankemeyer E; Hou C; Skovronsky D; Kilbourn M
Nucl Med Biol; 2008 Nov; 35(8):825-37. PubMed ID: 19026944
[TBL] [Abstract][Full Text] [Related]
6. Optimal scanning time window for 18F-FP-(+)-DTBZ (18F-AV-133) summed uptake measurements.
Lin KJ; Lin WY; Hsieh CJ; Weng YH; Wey SP; Lu CS; Skovronsky D; Yen TC; Chang CJ; Kung MP; Hsiao IT
Nucl Med Biol; 2011 Nov; 38(8):1149-55. PubMed ID: 21831650
[TBL] [Abstract][Full Text] [Related]
7. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters.
Goswami R; Ponde DE; Kung MP; Hou C; Kilbourn MR; Kung HF
Nucl Med Biol; 2006 Aug; 33(6):685-94. PubMed ID: 16934687
[TBL] [Abstract][Full Text] [Related]
8. Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters.
Kung MP; Hou C; Goswami R; Ponde DE; Kilbourn MR; Kung HF
Nucl Med Biol; 2007 Apr; 34(3):239-46. PubMed ID: 17383573
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Pancreatic VMAT2 Binding with Active and Inactive Enantiomers of [
Naganawa M; Lim K; Nabulsi NB; Lin SF; Labaree D; Ropchan J; Herold KC; Huang Y; Harris P; Ichise M; Cline GW; Carson RE
Mol Imaging Biol; 2018 Oct; 20(5):835-845. PubMed ID: 29468404
[TBL] [Abstract][Full Text] [Related]
10. Imaging of VMAT2 binding sites in the brain by (18)F-AV-133: the effect of a pseudo-carrier.
Zhu L; Qiao H; Lieberman BP; Wu J; Liu Y; Pan Z; Ploessl K; Choi SR; Chan P; Kung HF
Nucl Med Biol; 2012 Oct; 39(7):897-904. PubMed ID: 22749185
[TBL] [Abstract][Full Text] [Related]
11. PET Imaging of Vesicular Monoamine Transporter 2 in Early Diabetic Retinopathy Using [
Li J; Chen P; Bao Y; Sun Y; He J; Liu X
Mol Imaging Biol; 2020 Oct; 22(5):1161-1169. PubMed ID: 31650482
[TBL] [Abstract][Full Text] [Related]
12. Effects of anesthetics on vesicular monoamine transporter type 2 binding to ¹⁸F-FP-(+)-DTBZ: a biodistribution study in rat brain.
Chen Z; Tang J; Liu C; Li X; Huang H; Xu X; Yu H
Nucl Med Biol; 2016 Jan; 43(1):124-129. PubMed ID: 26526872
[TBL] [Abstract][Full Text] [Related]
13. An Efficient Automated Radiosynthesis and Bioactivity Confirmation of VMAT2 Tracer [
Zhao C; Liu C; Tang J; Xu Y; Xie M; Chen Z
Mol Imaging Biol; 2020 Apr; 22(2):265-273. PubMed ID: 31165386
[TBL] [Abstract][Full Text] [Related]
14. In vivo studies of the SERT-selective [18F]FPBM and VMAT2-selective [18F]AV-133 radiotracers in a rat model of Parkinson's disease.
Wang JL; Oya S; Parhi AK; Lieberman BP; Ploessl K; Hou C; Kung HF
Nucl Med Biol; 2010 May; 37(4):479-86. PubMed ID: 20447560
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of pancreatic VMAT2 binding with active and inactive enantiomers of
Naganawa M; Lin SF; Lim K; Labaree D; Ropchan J; Harris P; Huang Y; Ichise M; Carson RE; Cline GW
Nucl Med Biol; 2016 Dec; 43(12):743-751. PubMed ID: 27673755
[TBL] [Abstract][Full Text] [Related]
16. An improved radiosynthesis of [18F]AV-133: a PET imaging agent for vesicular monoamine transporter 2.
Zhu L; Liu Y; Plössl K; Lieberman B; Liu J; Kung HF
Nucl Med Biol; 2010 Feb; 37(2):133-41. PubMed ID: 20152712
[TBL] [Abstract][Full Text] [Related]
17. Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson's disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging.
Weng CC; Chen ZA; Chao KT; Ee TW; Lin KJ; Chan MH; Hsiao IT; Yen TC; Kung MP; Hsu CH; Wey SP
PLoS One; 2017; 12(3):e0173503. PubMed ID: 28257461
[TBL] [Abstract][Full Text] [Related]
18. In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133.
Okamura N; Villemagne VL; Drago J; Pejoska S; Dhamija RK; Mulligan RS; Ellis JR; Ackermann U; O'Keefe G; Jones G; Kung HF; Pontecorvo MJ; Skovronsky D; Rowe CC
J Nucl Med; 2010 Feb; 51(2):223-8. PubMed ID: 20080893
[TBL] [Abstract][Full Text] [Related]
19. Chronic manganism: A long-term follow-up study with a new dopamine terminal biomarker of 18F-FP-(+)-DTBZ (18F-AV-133) brain PET scan.
Huang CY; Liu CH; Tsao E; Hsieh CJ; Weng YH; Hsiao IT; Yen TC; Lin KJ; Huang CC
J Neurol Sci; 2015; 353(1-2):102-6. PubMed ID: 25936253
[TBL] [Abstract][Full Text] [Related]
20. Brain uptake of a non-radioactive pseudo-carrier and its effect on the biodistribution of [(18)F]AV-133 in mouse brain.
Wu X; Zhou X; Zhang S; Zhang Y; Deng A; Han J; Zhu L; Kung HF; Qiao J
Nucl Med Biol; 2015 Jul; 42(7):630-6. PubMed ID: 25910857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
